NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy

Skeletal Muscle

Volumn 4, Issue 1, 2014, Pages

  Kornegay, Joe N ^a,e   Peterson, Jennifer M ^d   Bogan, Daniel J ^a   Kline, William ^d   Bogan, Janet R ^a   Dow, Jennifer L ^a   Fan, Zheng ^a   Wang, Jiahui ^a   Ahn, Mihye ^b   Zhu, Hongtu ^b   Styner, Martin ^a,c   Guttridge, Denis C ^d,f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c Brooks Computer Science Building   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928106995     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-4-18     Document Type: Article

References (67)

1. Hoffman EP, Brown RH, Kunkel KM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928. 10.1016/0092-8674(87)90579-4.
2. Grounds MD: Two-tiered hypotheses for Duchenne muscular dystrophy. Cell Mol Life Sci 2008, 65:1621-1625. 10.1007/s00018-008-7574-8.
3. Manzur AY, Muntoni F: Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry 2009, 80:706-714. 10.1136/jnnp.2008.158329.
4. Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K: Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010, 25:1116-1129. 10.1177/0883073810371004.
5. Manzur AY, Kuntzer T, Pike M, Swan A: Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008, 1:CD003725.
6. Connolly AM, Schierbecker J, Renna R, Florence J: High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002, 12:917-925. 10.1016/S0960-8966(02)00180-3.
7. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270:286-290. 10.1126/science.270.5234.286.
8. Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G: Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 2003, 60:993-997. 10.1212/01.WNL.0000049913.27181.51.
9. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC: Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007, 117:889-901. 10.1172/JCI30556.
10. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663. 10.1146/annurev.immunol.18.1.621.
11. Perkins ND: Integrating cell-signaling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62. 10.1038/nrm2083.
12. Strickland I, Ghosh S: Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis 2006, 65:75-82.
13. Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfín DA, Dirienzo K, Clemens PR, Robbins PD, Baldwin AS, Flood P, Kaumaya P, Frietas M, Kornegay JN, Mendell JR, Rafael-Fortney JA, Guttridge DC, Janssen PM: Peptide-based inhibition of NF-ΚB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med 2011, 17:508-515.
14. Delfín DA, Xu Y, Peterson JM, Guttridge DC, Rafael-Fortney JA, Janssen PM: Improvement of cardiac contractile function by peptide-based inhibition of NF-ΚB in the utrophin/dystrophin-deficient murine model of muscular dystrophy. J Transl Med 2011, 9:68. 10.1186/1479-5876-9-68.
15. Lu A, Proto JD, Guo L, Tang Y, Lavasani M, Tilstra JS, Niedernhofer LJ, Wang B, Guttridge DC, Robbins PD, Huard J: NF-ΚB negatively impacts the myogenic potential of muscle-derived stem cells. Mol Ther 2012, 20:661-668. 10.1038/mt.2011.261.
16. Tang Y, Reay DP, Salay MN, Mi MY, Clemens PR, Guttridge DC, Robbins PD, Huard J, Wang B: Inhibition of the IKK/NF-ΚB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther 2010, 17:1476-1483. 10.1038/gt.2010.110.
17. Kornegay JN, Tuler SM, Miller DM, Levesque DC: Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 1988, 11:1056-1064. 10.1002/mus.880111008.
18. Cooper BJ, Winand WN, Stedman H, Valentine BA, Hoffman EP, Kunkel LM, Scott M-O, Fischbeck KH, Kornegay JN, Avery RJ, Williams JR, Schmickel RD, Sylvester JE: The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 1988, 334:154-156. 10.1038/334154a0.
19. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, Hung WY, Constantinou CD, Dykstra MJ, Roses AD, Bartlett RJ: An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1991, 13:115-121.
20. Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, Detwiler DA, Larsen CA, Grange RW, Bhavaraju-Sanka RK, Tou S, Keene BP, Howard JF Jr, Wang J, Fan Z, Schatzberg SJ, Styner MA, Flanigan KM, Xiao X, Hoffman EP: Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 2012, 23:85-108. 10.1007/s00335-011-9382-y.
21. Liu JMK, Okamura CS, Bogan DJ, Bogan JR, Childers MK, Kornegay JN: Effects of prednisone in canine muscular dystrophy. Muscle Nerve 2004, 30:767-773. 10.1002/mus.20154.
22. Lieber RL, Boakes JL: Sarcomere length and joint kinematics during torque production in frog hindlimb. Am J Physiol 1988, 254:C759-C768.
23. Kornegay JN, Bogan DJ, Bogan JR, Childers MK, Cundiff DD, Petroski GF, Schueler RO: Contraction torque generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophy. J Neurol Sci 1999, 166:115-121. 10.1016/S0022-510X(99)00118-5.
24. Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Grange RW: Golden retriever muscular dystrophy (GRMD): developing and maintaining a colony and physiological functional measurements. In Muscle Gene Therapy: Methods and Protocols. Methods in Molecular Biology, Volume 709. Edited by: Duan D. New York: Humana Press; 2011:105-123.
25. Childers MK, Grange RW, Kornegay JN: In vivo canine muscle function assay. J Vis Exp 2011, 50:e2623.
26. Tegler CJ, Grange RW, Bogan DJ, Markert DC, Case D, Kornegay JN, Childers MK: Eccentric contractions induce rapid isometric torque drop in dystrophic-deficient dogs. Muscle Nerve 2010, 42:130-132. 10.1002/mus.21699.
27. Kornegay JN, Sharp NJH, Bogan DJ, Van Camp SD, Metcalf JR, Schueler RO: Contraction tension and kinetics of the peroneus longus muscle in golden retriever muscular dystrophy. J Neurol Sci 1994, 123:100-107. 10.1016/0022-510X(94)90210-0.
28. Kornegay JNN, Sharp NJH, Schueler RO, Betts CW: Tarsal joint contracture in dogs with golden retriever muscular dystrophy. Lab Anim Sci 1994, 44:331-333.
29. Jaegger G, Marcellin-Little DJ, Levine D: Reliability of goniometry in Labrador retrievers. Am J Vet Res 2002, 63:979-986. 10.2460/ajvr.2002.63.979.
30. Nicholson HL, Osmotherly PG, Smith BA, McGowan CM: Determinants of passive hip range of motion in adult Greyhounds. Aust Vet J 2007, 85:217-221. 10.1111/j.1751-0813.2007.00145.x.
31. Wang J, Fan Z, Shiloh-Malawsky Y, An H, Kornegay JN, Styner MA: A computerized MRI biomarker quantification scheme for a canine model of Duchenne muscular dystrophy. Int J Comput Assist Radiol Surg 2013, 8:763-774. 10.1007/s11548-012-0810-6.
32. Fan Z, Wang J, Ahn M, Shiloh-Malawsky Y, Chahin N, Elmore S, Bagnell CR Jr, Wilber K, An H, Lin W, Zhu H, Styner M, Kornegay JN: Characteristics of magnetic resonance imaging biomarkers in a natural history study of golden retriever muscular dystrophy. Neuromuscul Disord 2014, 24:178-191. 10.1016/j.nmd.2013.10.005.
33. Hennig J, Weigel M, Scheffler K: Multiecho sequences with variable refocusing flip angles: optimization of signal behavior using smooth transitions between pseudo steady states (TRAPS). Magn Reson Med 2003, 49:527-535. 10.1002/mrm.10391.
34. Hennig J, Speck O, Scheffler K: Optimization of signal behavior in the transition to driven equilibrium in steady-state free precession sequences. Magn Reson Med 2002, 48:801-809. 10.1002/mrm.10274.
35. Herlidou S, Rolland Y, Bansard YL, Le Rumeur E, de Certaines JD: Comparison of automated and visual texture analysis in MRI: characterization of normal and diseased skeletal muscle. Magn Reson Imaging 1999, 17:1393-1397. 10.1016/S0730-725X(99)00066-1.
36. Mahmoud-Ghoneim D, Cherel Y, Lemaire L, de Certaines JD, Maniere A: Texture analysis of magnetic resonance images of rat muscles during atrophy and regeneration. Magn Reson Imaging 2006, 24:167-171. 10.1016/j.mri.2005.10.002.
37. Kornegay JN, Cundiff DD, Bogan DJ, Bogan JR, Okamura CS: The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy. Neuromuscul Disord 2003, 13:493-500. 10.1016/S0960-8966(03)00025-7.
38. Welch BL: The generalization of 'Student's' problem when several different population variances are involved. Biometrika 1947, 34:28-35.
39. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc: Series B 1995, 57:289-300.
40. Reay DP, Yang M, Watchko JF, Daood M, O'Day TL, Rehman KK, Guttridge DC, Robbins PD, Clemens PR: Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis 2011, 43:598-608. 10.1016/j.nbd.2011.05.008.
41. Li D, Yue Y, Duan D: Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am J Pathol 2008, 17:1332-1341.
42. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS, Fallon JR: Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A 2011, 108:762-767. 10.1073/pnas.1013067108.
43. Vignos PJ Jr, Archibald KC: Maintenance of ambulation in childhood muscular dystrophy. J Chronic Dis 1960, 12:273-290. 10.1016/0021-9681(60)90105-3.
44. Siegel IM, Miller JE, Ray RD: Subcutaneous lower limb tenotomy in the treatment of pseudohypertrophic muscular dystrophy. J Bone Joint Surg 1968, 50A:1437-1443.
45. Rideau Y: Treatment of orthopedic deformity during the ambulation stage of Duchenne muscular dystrophy. In Neuromuscular Diseases. Edited by: Serratrice G. New York: Raven; 1984:557-564.
46. Thibaud J, Monnet A, Bertoldi D, Barthelemy I, Blot S, Carlier P: Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs by nuclear magnetic resonance imaging. Neuromuscul Disord 2007, 17:575-584. 10.1016/j.nmd.2007.03.013.
47. Kobayashi M, Nakamura A, Hasegawa D, Fujita M, Orima H, Takeda S: Evaluation of dystrophic dog pathology by fat-suppressed T2-weighted imaging. Muscle Nerve 2009, 40:815-826. 10.1002/mus.21384.
48. Thibaud JL, Azzabou N, Barthelemy I, Fleury S, Cabrol L, Blot S, Carlier PG: Comprehensive longitudinal characterization of canine muscular dystrophy by serial NMR imaging of GRMD dogs. Neuromuscul Disord 2012,22(Suppl. 2):S85-S99.
49. Yokota T, Lu Q-L, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E: Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009, 65:667-676. 10.1002/ana.21627.
50. Shmuel DL, Cortes Y: Anaphylaxis in dogs and cats. J Vet Emerg Crit Care (San Antonio) 2013, 23:377-394. 10.1111/vec.12066.
51. Ohmori K, Masuda K, Maeda S, Kaburagi Y, Kurata K, Ohno K, Deboer DJ, Tsujimoto H, Sakaguchi M: IgE reactivity to vaccine components in dogs that developed immediate-type allergic reactions after vaccination. Vet Immunol Immunopathol 2005, 104:249-256. 10.1016/j.vetimm.2004.12.003.
52. Cook MC, Basten A, Fazekas de St Groth B: Outer periarteriolar lymphoid sheath arrest and subsequent differentiation of both naive and tolerant immunoglobulin transgenic B cells is determined by B cell receptor occupancy. J Exp Med 1997, 29:631-643.
53. Francis AH, Martin LG, Haldorson GJ, Lahmers KK, Luther TY, Alperin DC, Hines SA: Adverse reactions suggestive of type III hypersensitivity in six healthy dogs given human albumin. J Am Vet Med Assoc 2007, 230:873-879. 10.2460/javma.230.6.873.
54. Ruegg UT: Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 2013, 26:577-584. 10.1097/WCO.0b013e328364fbaf.
55. Konieczny P, Swiderski K, Chamberlain JS: Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 2013, 47:649-663. 10.1002/mus.23738.
56. Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G: Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 2006, 168:918-926. 10.2353/ajpath.2006.050673.
57. Carlson CG, Samadi A, Siegel A: Chronic treatment with agents that stabilize cytosolic IkappaB-alpha enhances survival and improves resting membrane potential in MDX muscle fibers subjected to chronic passive stretch. Neurobiol Dis 2005, 20:719-730. 10.1016/j.nbd.2005.05.003.
58. Hnia K, Gayraud J, Hugon G, Ramonatxo M, De La Porte S, Matecki S, Mornet D: L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol 2008, 172:1509-1519. 10.2353/ajpath.2008.071009.
59. Pan Y, Chen C, Shen Y, Zhu CH, Wang G, Wang XC, Chen HQ, Zhu MS: Curcumin alleviates dystrophic muscle pathology in mdx mice. Mol Cells 2008, 25:531-537.
60. Siegel AL, Bledsoe C, Lavin J, Gatti F, Berge J, Millman G, Turin E, Winders WT, Rutter J, Palmeiri B, Carlson CG: Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse. Neuromuscul Disord 2009, 19:131-139. 10.1016/j.nmd.2008.10.006.
61. Peterson JM, Bakkar N, Guttridge DC: NF-ΚB signaling in skeletal muscle health and disease. Curr Top Dev Biol 2011, 96:85-119.
62. Cross SH, Allshire RC, McKay SJ, McGill NI, Cooke HJ: Cloning of human telomeres by complementation in yeast. Nature 1989, 338:771-774. 10.1038/338771a0.
63. Argyle DJ, Nasir L: Telomerase: a potential diagnostic and therapeutic tool in canine oncology. Vet Pathol 2003, 40:1-7. 10.1354/vp.40-1-1.
64. Szebeni J, Alving CR, Rosivall L, Bünger R, Baranyi L, Bedöcs P, Tóth M, Barenholz Y: Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res 2007, 17:107-117. 10.1080/08982100701375118.
65. de Mora F, Puigdemont A, Torres R: The role of mast cells in atopy: what can we learn from canine models? A thorough review of the biology of mast cells in canine and human systems. Br J Dermatol 2006, 155:1109-1123. 10.1111/j.1365-2133.2006.07494.x.
66. Rushe M, Silvian L, Bixler S, Chen LL, Cheung A, Bowes S, Cuervo H, Berkowitz S, Zheng T, Guckian K, Pellegrini M, Lugovskoy A: Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure 2008, 16:798-808. 10.1016/j.str.2008.02.012.
67. Habineza Ndikuyeze G, Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Flood P, Krick E, Propert KJ, Mason NJ: A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. PLoS One 2014, 9:e95404. 10.1371/journal.pone.0095404.